Pindolol augmentation enhances response outcomes in first depressive episodes

Maria J. Portella, Javier de Diego-Adeliño, Dolors Puigdemont, Rosario Pérez-Egea, Enric Álvarez, Francesc Artigas, Víctor Pérez

Research output: Contribution to journalArticleResearchpeer-review

23 Citations (Scopus)

Abstract

Effectiveness of Pindolol addition to SSRIs is still a matter of debate. Recently, Geretsegger et al. [Geretsegger, C., Bitterlich, W., Stelzig, R., Stuppaeck, C., Bondy, B. and Aichhorn, W. (2008) Paroxetine with Pindolol augmentation: a double-blind, randomized, placebo-controlled study in depressed in-patients. Eur. Neuropsychopharmacol. 18, 141-146.] have found that never-medicated depressed patients showed a significant sustained response with Paroxetine + Pindolol treatment. Also, patients with a first depressive episode displayed a trend for higher sustained response rates with Pindolol co-administration. Re-analysing the data of a previous clinical trial of Fluoxetine + Pindolol [Pérez, V., Gilaberte, I., Faries, D., Alvarez, E. and Artigas, F. (1997). Randomised, double-blind, placebo-controlled trial of Pindolol in combination with Fluoxetine antidepressant treatment. Lancet 349, 1594-1597.], we have found that first depressive episodes are associated with a significant higher percentage of sustained responses when administering Fluoxetine + Pindolol (70.3%) compared to Fluoxetine + Placebo (44%). Moreover, based on a survival analysis, among the patients with a first depressive episode, those who received Fluoxetine + Pindolol achieved a sustained response significantly earlier (19 days) than those on Fluoxetine + Placebo (35 days). Interestingly, none of these effects were observed in the subsample of recurrent patients. The results suggest that Pindolol augmentation accelerates and enhances the action of SSRI at the beginning of the illness. © 2009 Elsevier B.V. All rights reserved.
Original languageEnglish
Pages (from-to)516-519
JournalEuropean Neuropsychopharmacology
Volume19
Issue number7
DOIs
Publication statusPublished - 1 Jul 2009

Keywords

  • Depressive disorder
  • First episode
  • Fluoxetine
  • Paroxetine
  • Pindolol
  • SSRI

Fingerprint Dive into the research topics of 'Pindolol augmentation enhances response outcomes in first depressive episodes'. Together they form a unique fingerprint.

  • Cite this

    Portella, M. J., de Diego-Adeliño, J., Puigdemont, D., Pérez-Egea, R., Álvarez, E., Artigas, F., & Pérez, V. (2009). Pindolol augmentation enhances response outcomes in first depressive episodes. European Neuropsychopharmacology, 19(7), 516-519. https://doi.org/10.1016/j.euroneuro.2009.04.004